Balaxi Pharmaceuticals' Q1 FY 2025-26 Quarterly Results

Result Summary

• Balaxi Pharmaceuticals Ltd reported a 18.8% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 8.2%.
• Its expenses for the quarter were up by 42.9% QoQ and 20.7% YoY.
• The net profit decreased 97.3% QoQ and decreased 95.5% YoY.
• The earnings per share (EPS) of Balaxi Pharmaceuticals Ltd stood at 0.1 during Q1 FY 2025-26.

Financial Statments for Q1 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Balaxi Pharmaceuticals Ltd is a company operating in the pharmaceutical industry. The company is primarily engaged in the manufacturing and distribution of pharmaceutical products. It focuses on the production of generic medicines and over-the-counter (OTC) drugs, catering to a broad market with its extensive product portfolio. The company has been working towards expanding its market presence and enhancing its product offerings to meet the growing demands in the healthcare sector. As of the latest available data, further specific details about recent developments or strategic initiatives undertaken by Balaxi Pharmaceuticals are not available.

Revenue

For the first quarter of the fiscal year 2026 (Q1FY26), Balaxi Pharmaceuticals Ltd reported a total income of ₹68.97 crores. This represents an 18.8% increase in revenue compared to the previous quarter (Q4FY25), where the total income was ₹58.05 crores. Additionally, there was an 8.2% year-over-year increase from the ₹63.77 crores recorded in the first quarter of fiscal year 2025 (Q1FY25). These changes in revenue highlight a positive trend in the company's income over both the quarterly and annual periods.

Profitability

During Q1FY26, Balaxi Pharmaceuticals Ltd experienced significant changes in its profitability metrics. The Profit Before Tax (PBT) was ₹0.90 crores, which marked a substantial decline of 92.2% from the ₹11.49 crores in the previous quarter (Q4FY25) and an 87.8% decrease year-over-year from ₹7.37 crores in Q1FY25. The company's Profit After Tax (PAT) also saw a notable decrease, amounting to ₹0.29 crores in Q1FY26. This reflects a 97.3% drop compared to the previous quarter and a 95.5% reduction from the same quarter last year. Consequently, Earnings Per Share (EPS) for Q1FY26 was ₹0.10, down 99.0% from ₹10.40 in Q4FY25 and 91.7% from ₹1.20 in Q1FY25.

Operating Metrics

The total expenses for Balaxi Pharmaceuticals Ltd in Q1FY26 were reported at ₹68.06 crores. This indicates a 42.9% increase from the previous quarter's expenses of ₹47.64 crores and a 20.7% rise from the ₹56.40 crores recorded in Q1FY25. The tax expense in Q1FY26 was ₹0.61 crores, which is an 8.9% increase from Q4FY25's tax of ₹0.56 crores but a 31.5% decrease compared to the ₹0.89 crores tax expense in Q1FY25. These figures reflect various shifts in the company's operating costs and tax obligations over the periods in question.